Purpose. We recently described two types of stromal response in breast cancer derived from gene expression studies of tenosynovial giant cell tumors and fibromatosis. The purpose of this study is to elucidate the basis of this stromal response -whether they are elicited by individual tumors or whether they represent an endogenous host reaction produced by the patient.
breast cancers. Synchronous, independent primaries were defined as invasive carcinomas that either presented in separate breasts or as two clinically distinct carcinomas within the same breast. 26 patients with archival formalin fixed paraffin embedded tissue were identified with synchronous independent primary breast cancers for a total of 52 cases.
(TA228, Table 1 ). In order to specifically study the stromal responses between normal, malignant, and biopsy site changes, a second tissue microarray (TMA 242) was constructed using the same material as that used in the breast scar gene expression profiling studies (see below). Areas representing a range of lesions were taken, including normal breast tissue (27 spots), granulomatous mastitis (2), previous biopsy sites (27), ductal carcinoma in-situ, DCIS (1), infiltrating ductal carcinoma, IDC (19) , and infiltrating lobular carcinoma, ILC (2) for a total of 78 tissues.
Evaluation of epithelial markers. Tissue sections were deparaffinized followed by blockade of endogeneous peroxidases and antigen retrieval using Antigen Unmasking Solution (Vector; USA). Estrogen receptor (ER) clone 1D5 using a dilution of 1:1000, following a 15 minute pre-treatment in citrate buffer, pH = 6.0; progesterone receptor (PR) (BioGenex, San Ramon, CA) clone PR88 using a dilution of 1:100 following an 18 minute pre-treatment in citrate buffer pH = 6.0; and Her-2/neu (Dako, Carpinteria, CA)
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The slides were then counterstained in hematoxylin, dehydrated, and mounted. Positive and negative controls were performed. HER2 was defined as positive if IHC was 3+
(strong circumferential membranous staining). It was considered negative in those tumors scoring 0-1+ (no to weak, non-circumferential staining). For those tumors with a 2+ score on IHC, gene amplification using FISH was used to determine HER2 status.
HER2 was considered positive if the ratio of the copies of chromosome 17 to the number of HER2 gene copies was >2. Cellular proliferation was assessed by measurement of Ki-67 antigen by MIB-1 antibody (DAKO, Carpinteria, CA), scoring the percentage of positive cells. Ki-67 was stratified into 4 levels depending on percentage of nuclear labeling: score=0, <5% labeling; score=1, 5-10% labeling; score=2, 10-25% labeling, score=3, >25% labeling. Nottingham grade was scored using the modified Scarff-Bloom- Similarly, comparisons were performed for CSF1 response profile between normal stroma and biopsy site stroma (12 sets) and between normal stroma and stroma surrounding carcinoma (8 sets). Lastly, Spearman correlation between DTF and CSF1 marker expression and days following biopsy was computed to assess for an association of marker expression with days following biopsy.
Breast scar gene expression array.
In order to study the overall pattern of CSF1 and DTF marker expression in the context of breast scar tissue, expression profiling with gene microarrays were performed using material taken from archival material from a separate set of 16 patients seen at Stanford University Medical Center. Total RNA was isolated by using the RecoverAll Total digestion. DNase treatment and final purification were performed using a filter cartridge.
The total RNA was eluted in 60 µL of RNase-free water, quantified, aliquoted, and stored at -80°C until use. Total RNA was amplified by using the Sense AMP RNA amplification kit (Genisphere Inc, Hatfield, PA). 250ng of total RNA was heated at 80ºC for 10 minutes with dT and random primers. The Genisphere SenseAmp linear mRNA amplification method produces sense-strand amplified mRNA by incorporating a double stranded T7 promoter into the 3' end of the first strand cDNA, driving transcription of an amplified RNA with the same strandedness as mRNA. RNA amplification was carried out according to the manufacturers' instructions. The amplified Sense RNA (aRNA) was purified using the Rneasy minElute Cleanup Kit (Qiagen) and the eluate was collected in 15 µL RNase-free water. Amplified Sense RNA purity was determined by using a spectrophotometer to evaluate the A260/280 ratio. The fold-amplifications were evaluated by assuming that mRNA constitutes 1% to 5% of a total RNA population and only 20% of Sense RNA obtained from amplification was estimated to be true mRNA, whereas the rest could be amplified ribosomal RNA (http://www.genisphere.com/rna_amp_faqs.html and Sense AMP RNA amplification kit data sheet). The Human Exonic Evidence Based Oligonucleotide microarrays (HEEBO, Stanford) which contain 44,544 70-mer probes that were designed using a transcriptome-based annotation of exonic structure for genomic loci were used for expression profiling. The 5-10ug of amplified RNA was reverse-transcribed into cDNA using a mixture of oligo dT and random hexamer primers with incorporation of amino allyl-dUTP. Cy3 and Cy5 dyes were used for indirect labeling of the cDNA from amplified reference RNA (universal human reference RNA) and cDNA from amplified
Results

Stromal response in paired breast primaries
In prior studies we found that subsets of breast cancers are associated with discrete stromal gene signatures (5, 6, 13) . To gain insight as to whether these signatures are initiated by the individual tumors or are specific to the host, we looked for intra-patient variation of both the DTF fibroblast and the CSF1 macrophage response signatures in 26 pairs of breast cancer samples from patients with dual breast primaries. The 52 breast cancer samples were assessed for these two signatures by immunohistochemistry using previously defined sets of 5 biomarkers for the DTF fibroblast signature (cadherin 11, MMP 11, CSPG2, CD138, and osteonectin) and 4 biomarkers for the CSF1 macrophage response signature (cathepsin L, CD163, CD16, CD32)(6, 13, 16).
The mean level of expression of DTF fibroblast response markers showed significantly less intra-patient discordance, i.e. more similarity, in matched primaries compared with the discordance observed in pairs of tumors from different patients (mean discordance = 0.78 in matched pairs vs. 1.21 in random pairs; p=0.007) [ Table 2 ]. In contrast, the expression of CSF1 macrophage response markers did not show significantly more agreement in matched pairs from a single patient compared with un-matched pairs from separate patients (mean discordance = 0.71 in matched pairs vs. 0.80 in random pairs; p=0.22) [ Table 2 ]. When examined individually, all DTF markers but only 2 of the 4 CSF1 markers show a trend for more concordance in matched primaries compared with random pairs (all p<0.10) [ Table 2 ].
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We also sought to assess the conservation of a set of additional biomarkers (ER, PR, Her2neu, Ki-67) and tumor characteristics (histologic subtype, tumor grade, size, laterality) in paired breast primaries. ER, PR and Her2neu could not be examined due to the lack of variation among the specimens. For the rest of the markers and tumor characteristics evaluated, only Ki-67 showed significant correlation between the two primaries (p=0.014) [ Table 2 ]. There was no difference between the amount of stromal component in the breast primaries.
Stromal signature concordance within matched patient samples across normal, biopsy site and invasive carcinoma
To further characterize these stromal signatures in the overall setting of tissue injury response, we compared CSF1 macrophage and DTF fibroblast response patterns in the setting of normal breast, prior biopsy site, and invasive carcinoma by gene expression profiling. Cluster analysis for both the CSF1 macrophage and the DTF fibroblast core gene lists showed variation of signature profiles among patients in biopsy site stroma ( Figure 1 ). This finding suggests that the CSF1 macrophage and DTF fibroblast response patterns show variable patterns of expression in biopsy site stroma, a process that we have previously characterized in breast cancer stroma (5, 6, 13) .
To analyze these variations in detail, a tissue microarray of normal, biopsy site, and carcinoma-related stroma was constructed and analyzed with immunohistochemistry using the CSF1 macrophage and DTF fibroblast markers (Figure 2 ). The DTF fibroblast signature showed more concordance across normal, cancer, and biopsy site samples from that the CSF1 response is not generated as a generalized response to tissue disruption.
Analysis of temporal relationship of stromal marker expression with days following biopsy
To assess temporal alterations in stromal marker expression, Spearman correlation was computed between DTF/CSF1 scores and number of days following initial core biopsy (Table 5) whether the stromal response is a generalized response to tissue injury, or a specific response generated in reaction to the inciting tumor. We addressed this question by examining stromal signatures in normal breast, biopsy site changes, and carcinoma. If the stromal response is a tumor-specific reaction, we would anticipate significant differences in stromal signature response between biopsy site changes and carcinoma. If the stromal response is a more generalized response to tissue injury, we would anticipate significant differences in stromal signature response between normal tissue and biopsy site changes, but negligible differences between biopsy site changes and carcinoma. We then studied stromal response to biopsy site changes and carcinoma to delineate tumor-specific response from a more generalized tissue injury response. In doing so, we found that the two stromal signatures have divergent associations.
Our studies indicate that the DTF fibroblast response signature is significantly conserved in patients with paired breast primaries. In examining stroma taken from normal breast and biopsy site changes, we find that the response to biopsy site changes is similar to the response to carcinoma, and conclude that DTF fibroblast response is a more generalized response to tissue disruption and injury that appears to be specific to individual patients.
This suggests that the DTF fibroblast response is a host-specific response and that the ability to generate this response varies between patients.
In contrast to the DTF fibroblast response, which showed significant concordance within a patient, the CSF1 macrophage response showed no significant concordance within patients with paired breast primaries. However, we cannot exclude that in a larger patient be that the CSF1 macrophage response is at least in part invoked by tumor.
These findings are in keeping with a separate study in our group on colon and breast cancer metastases, which demonstrated that DTF stromal expression is dependent on the tissue type (lymph node versus colon), while CSF1 stromal expression is conserved within the same tumor regardless of tissue background (17) . This finding complements our conclusions from studying breast cancer, in that DTF appears to be not only patient specific, but tissue specific, while CSF1 response may be dependent on the individual tumor characteristics.
We have demonstrated two divergent stromal responses to breast cancer by studying marker expression in patients with synchronous breast primaries. A potential confounding factor would be if a patient developed two biologically similar tumors that would then induce the same stromal response. To evaluate whether epithelial markers were more conserved in paired primaries than would be expected by chance, we analyzed the paired breast primaries for conventional tumor biomarkers (ER, PR, Her2neu, and Ki-67) and tumor characteristics (histologic subtype, tumor grade, size, laterality). Of these features, the only one that attained statistical significance for concordance in paired primaries was Ki67 (p= 0.014), suggesting that proliferative index may be conserved in dual primaries. Due to the relatively small sample size and small amount of total Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research variation in ER, PR and Her2neu across all the samples, our study was underpowered for identifying statistically significant conservation of these markers among paired primaries.
We did not find any evidence of significant conservation of these makers, but we note that this hypothesis needs to be evaluated in a larger study with higher proportions of hormone receptor negative and Her2 positive patients. Taken together, our findings are consistent with evidence in the literature suggesting that dual breast primaries show distinct patterns of molecular alterations, based on molecular studies (18, 19) , histologic subtype and hormonal receptor status (20) (21) (22) , and by cytogenetics (23).
The interaction of cancer and stroma is reminiscent of the seed and soil theory proposed by Stephen Paget in 1889 to explain the preferential metastases of breast cancer to sites such as bone (24) . In the case of cancer treatment, therapy has predominantly relied on attacking the "seed," i.e. the epithelial component. Study of the "soil," or the stroma, allows for understanding of the tumor microenvironment and opens up possibilities for a different direction of therapy. The study of the milieu in which breast cancer is situated is challenging, as the stromal response may be a product of tumor provocation as well as the patient's innate healing mechanism. In this paper, we have attempted a better understanding of this "soil," in hopes that knowledge of the stromal response can in the future lead to novel treatments which create less fertile grounds for tumor growth. Norm = stroma surrounding normal breast tissue, Bx = stroma surrounding biopsy site, Ca = stroma surrounding carcinoma.
Response column calculated by taking average of stromal response to biopsy and carcinoma, and subtracting from normal stromal expression. 
